Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Oleg Nodelman Biography and Net Worth

Director of Nuvation Bio

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With nearly twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company focused on the discovery and development of novel therapies. Mr. Nodelman is also the CEO and Chairman of Panacea Acquisition Corp (NYSE: PANA). Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. (Mr. Nodelman will become a director upon completion of the pending merger between Nuvation Bio and Panacea Acquisition Corp.)

What is Oleg Nodelman's net worth?: The estimated net worth of Oleg Nodelman is at least $32.76 million as of February 21st, 2023. Mr. Nodelman owns 12,674,775 shares of Nuvation Bio stock worth more than $32,764,293 as of November 20th. This net worth estimate does not reflect any other assets that Mr. Nodelman may own. Learn More about Oleg Nodelman's net worth.
How do I contact Oleg Nodelman?: The corporate mailing address for Mr. Nodelman and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at [email protected]. Learn More on Oleg Nodelman's contact information.
Has Oleg Nodelman been buying or selling shares of Nuvation Bio?: Oleg Nodelman has not been actively trading shares of Nuvation Bio during the last ninety days. Most recently, on Tuesday, February 21st, Oleg Nodelman bought 53,000 shares of Nuvation Bio stock. The stock was acquired at an average cost of $1.36 per share, with a total value of $72,080.00. Following the completion of the transaction, the director now directly owns 12,674,775 shares of the company's stock, valued at $17,237,694. Learn More on Oleg Nodelman's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Jennifer Fox (CFO & Sec. ), David Hung (Founder), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 4 times. They purchased a total of 696,778 shares worth more than $1,985,500.47. The most recent insider tranaction occured on October, 8th when Director Robert Mashal bought 100,000 shares worth more than $220,000.00. Insiders at Nuvation Bio own 5.1% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 10/8/2024.

Oleg Nodelman Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2023	Buy	53,000	$1.36	$72,080.00	12,674,775
2/19/2023	Buy	5,143,000	$1.26	$6,480,180.00	12,504,675
11/24/2021	Buy	185,026	$7.69	$1,422,849.94
7/31/2021	Buy	56,598	$8.64	$489,006.72
4/12/2021	Buy	133,000	$9.49	$1,262,170.00
4/9/2021	Buy	300,000	$10.03	$3,009,000.00
3/31/2021	Buy	151,544	$10.45	$1,583,634.80

Oleg Nodelman Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $2.59

$2.50

$2.62

50 Day Range

MA: $2.52

$2.00

$3.07

2 Week Range

Now: $2.59

$1.21

$4.16

Volume

3,589,565 shs

Average Volume

2,093,834 shs

Market Capitalization

$870.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.